Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

The European Union's drug regulator on Friday recommended conditional authorisation of Madrigal Pharmaceuticals' Rezdiffra, ...

Review the current Madrigal Pharmaceuticals Inc (MDGL:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if MDGL is the best investment for you.

Earlier this year, Madrigal Pharmaceuticals (NASDAQ: MDGL) launched its first product, Rezdiffra. It wasn't just an important breakthrough for the mid-cap biotech; Rezdiffra became the first ...

Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.

Check out our MDGL stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease ...

Conshohocken, Pennsylvania Monday, June 23, 2025, 13:30 Hrs [IST] ...

The USDA is considering vaccinating poultry against bird flu, potentially influencing exports while causing significant ...

The USDA considers vaccinating poultry for bird flu, while the EU supports Madrigal's liver drug Rezdiffra. Meanwhile, the ...

Short interest in Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) increased during the last reporting period, rising from 4.03M to 4.10M. This put 21.43% of the company's publicly available shares ...